Halozyme to acquire Elektrofi for $750M upfront, expanding drug delivery offerings into 2040s

HALOZYME THERAPEUTICS, INC.

Upfront payment $750M; up to three $50M milestones contingent on product regulatory approvals.
Hypercon technology enables 400-500 mg/ml concentrations, up to 4-5x standard aqueous formulations.
Two partner products expected to begin clinical development by year-end 2026 or earlier.
Royalty revenue expected to begin 2030; deal less than 5% dilutive to Non-GAAP EPS over medium term.
Halozyme reaffirms 2025 guidance: rev $1.275-1.355B, Adj EBITDA $865-915M, Non-GAAP EPS $6.00-6.40.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.